Molecular analysis of apoptosis related genes DNA methylation status in endometrial carcinogenesis

Aberrant methylation in the promoters of genes associated with apoptosis was observed in many human cancers, but in the context of endometrial cancer only few publications have described the DNA methylation status of these genes. Apoptosis is a program cell death to maintain a tissue homeostasis in normal menstrual cycle. Disturbances in this pathway can promote cancer cell survival and furthermore are associated with resistance to therapy in endometrial cancer. Despite a high curability of this cancer type, prognosis of patients with advanced disease is still poor. One of the major mechanism of resistance to therapy is the aberrant DNA methylation pattern. Analysis of aberrant DNA methylation status can reveal early biomarkers in endometrial tumorigenesis and reflect apoptosis resistance development

A population-based study of glutathione-S-transferase M1, T1 and P1 genotypes

A retrospective study on healthy, unrelated subjects was conducted in order to estimate population glutathione-S-transferases (GST) genotype frequencies in Slovak population of men and compare our results with already published data (GSEC project)^1^. A further aim of the study was to evaluate frequencies of the _GST_ polymorphisms also in patients with prostate cancer in order to compare the evaluated proportions with those found in the control subjects. Analysis for the _GST_ gene polymorphisms was performed by PCR and PCR-RFLP. We found that the proportions are not significantly different from those estimated in a European multicentre study or from the results published by another group in Slovakia. We found significantly increased age-standardized prostate cancer prevalence rates in the carriers of _GSTM1_ null genotype (P = 0.037) and trend for such an increase in the carriers of _GSTP1_ polymorphism when compared with the respective groups of non-carriers. Because understanding of the contribution of _GST_ gene polymorphisms and their interactions with other relevant factors may improve screening diagnostic assays for prostate cancer, we discuss issues of study feasibility, study design, and statistical power, which should be taken into account in planning further trials

Global methylation status in malignant brain tumor tissue

The DNA methylation is one of the main epigenetic inheritance form, which contributes in the regulation of gene expression. Abnormalities in DNA methylation processes can provide information about many pathophysiological conditions, including tumorigenesis. DNA hypomethylation was the initial epigenetic abnormality recognized in human tumors. Glioblastoma (GB) is the most common and the most aggressive primary brain tumor in adults and therefore is considered one of the major issue in modern medicine

Polymorphisms of glutathione-S-transferase M1, T1, P1 and the risk of prostate cancer: a case-control study

<p>Abstract</p> <p>Background</p> <p>It has been suggested that polymorphisms in glutathione-<it>S</it>-transferases (GST) could predispose to prostate cancer through a heritable deficiency in detoxification pathways for environmental carcinogens. Yet, studies linking <it>GST </it>polymorphism and prostate cancer have so far failed to unambiguously establish this relation in patients. A retrospective study on healthy, unrelated subjects was conducted in order to estimate the population <it>GST </it>genotype frequencies in the Slovak population of men and compare our results with already published data (GSEC project-Genetic Susceptibility to Environmental Carcinogens). A further aim of the study was to evaluate polymorphisms in <it>GST </it>also in patients with prostate cancer in order to compare the evaluated proportions with those found in the control subjects.</p> <p>Methods</p> <p>We determined the <it>GST </it>genotypes in 228 healthy, unrelated subjects who attended regular prostate cancer screening between May 2005 and June 2007 and in 129 histologically verified prostate cancer patients. Analysis for the <it>GST </it>gene polymorphisms was performed by PCR and PCR-RFLP.</p> <p>Results</p> <p>We found that the <it>GST </it>frequencies are not significantly different from those estimated in a European multicentre study or from the results published by another group in Slovakia. Our results suggest that <it>Val/Val </it>genotype of <it>GSTP1 </it>gene could modulate the risk of prostate cancer, even if this association did not reach statistical significance. We did not observe significantly different crude rates of the <it>GSTM1 </it>and <it>GSTT1 </it>null genotypes in the men diagnosed with prostate cancer and those in the control group.</p> <p>Conclusion</p> <p>Understanding the contribution of <it>GST </it>gene polymorphisms and their interactions with other relevant factors may improve screening diagnostic assays for prostate cancer. We therefore discuss issues of study feasibility, study design, and statistical power, which should be taken into account in planning further trials.</p